Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study
A midstage study of the drug in celiac disease remains ongoing, with results expected in the second half of 2026, the company said
Meta-analysis conducted by Cui and coauthors which included 761 esophageal and gastric cancer cases and 457 controls demonstrated a strong association of PLCE1 expression with tumor progression in esophageal squamous cell carcinoma (ESCC) and gastric cancer (GC) [27]
With their proven effectiveness and safety, GLP-1 receptor agonists (GLP-1 RAs) have become the leading weight-loss medications worldwide, prompting the pharmaceutical industry to ramp up research and development efforts in this area
Theres a lot to know about how they work, the current off-brand use, and the risks